To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Can BDDCS illuminate targ… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Can BDDCS illuminate targets in drug design?

Journal article
Authors G. Bocci
L. Z. Benet
Tudor I Oprea
Published in Drug Discovery Today
Volume 24
Issue 12
Pages 2299-2306
ISSN 1359-6446
Publication year 2019
Published at Institute of Medicine, Department of Rheumatology and Inflammation Research
Pages 2299-2306
Language en
Links dx.doi.org/10.1016/j.drudis.2019.09...
Keywords classification, transporters, disposition, prediction, mechanism, Pharmacology & Pharmacy
Subject categories Pharmacology and Toxicology

Abstract

The fact that pharmacokinetic (PK) properties of drugs influence their interaction with protein targets is a principle known for decades. The same cannot be said for the opposite, namely that targets influence the PK properties of drugs. Evidence confirming this possibility is introduced here for the first time, as we show that certain protein families have a clear preference for drugs with specific PK properties. We investigate this by cross-referencing 'druggable target' annotations for >1000 US Food and Drug Administration (FDA)-approved drugs with their PK profile, as defined by the Biopharmaceutics Drug Disposition Classification System (BDDCS) criteria, and then examine the BDDCS preference for several major target protein families and therapeutic categories. Our findings suggest a novel way to conduct drug discovery by focusing PK profiles at the very early stage of target selection.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?